These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 18222951

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ, Liu HY, Lin YC, Sun KL, Chun CL, Hsueh PR.
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
    Guss J, Abuzeid WM, Doghramji L, Edelstein PH, Chiu AG.
    ORL J Otorhinolaryngol Relat Spec; 2009 Mar; 71(5):263-7. PubMed ID: 19797934
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
    Jónsdóttir K, Kristinsson KG.
    Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
    Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW.
    Clin Infect Dis; 2003 Sep 15; 37(6):745-51. PubMed ID: 12955633
    [Abstract] [Full Text] [Related]

  • 15. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
    Rossolini GM, Mantengoli E.
    Clin Microbiol Infect; 2005 Jul 15; 11 Suppl 4():17-32. PubMed ID: 15953020
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW.
    Clin Infect Dis; 2008 Mar 15; 46(6):862-7. PubMed ID: 18279040
    [Abstract] [Full Text] [Related]

  • 19. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN, Micek ST, Reichley RM, Ritchie DJ.
    Clin Ther; 2009 Feb 15; 31(2):299-310. PubMed ID: 19302902
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.